Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...

Debate over childhood obesity treatments: weight-loss drugs vs. lifestyle changes, with concerns about long-term effects.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...